3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory).

This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus.

Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life.